IBS

Irritable bowel syndrome is one of the most common conditions almost nobody brings up at dinner. It is also one of the few where the rulebook was rewritten a few months ago — so some of what you have read about it is already out of date.

Photo: Vlada Karpovich / https://www.pexels.com

Do you, or does someone you know, live with IBS? There is a decent chance the answer is yes and nobody has said so out loud.

Cleveland Clinic estimates that 10–15% of US adults have IBS, and that only about 5–7% of adults ever see a provider and receive the diagnosis — which works out to roughly half the people who have it walking around without a name for it.¹ Research surveys using stricter criteria land lower: the most recent global survey, published in August 2026, puts IBS at 8.5% of adults worldwide.⁶ Either way it is common, it is under-diagnosed, and it is very badly served by the internet.

So here is the current picture: what IBS actually is, what changed this year, what the evidence supports, and what it does not.

What IBS actually is

Photo: Mogomotsi Makolo / https://www.pexels.com

IBS is a disorder of gut–brain interaction, or DGBI — the term the field now uses in place of "functional gastrointestinal disorder."^3,9 The change is not cosmetic. "Functional" had drifted into meaning "we could not find anything," and that is not what is going on.

The Rome Foundation, which writes the definitions, describes DGBI as gastrointestinal symptoms arising from some combination of disturbed motility, visceral hypersensitivity, altered mucosal and immune function, altered gut microbiota, and altered processing in the central nervous system.³ In plainer terms: the plumbing is intact and the signaling is not.

Food moves through too quickly, too slowly, or unpredictably between the two. The nerves in the gut wall report ordinary sensations — a normal amount of gas, a normal amount of stretch — as painful. And the two-way traffic along the gut–brain axis runs differently. None of that is imaginary. It just does not show up on a scope, which is a limitation of the scope.

IBS is not "nothing wrong." It is something wrong with how the gut and the brain talk to each other.

The rules changed in 2026

The Rome criteria are the symptom checklists gastroenterologists and researchers use to define IBS. Rome IV, published in 2016, required recurrent abdominal pain on average at least one day a week over three months, together with at least two of: pain related to defecation, a change in stool frequency, or a change in stool form.⁹

Rome V arrived in May 2026 and loosened two things. "Discomfort" is back alongside "pain" — Rome IV had removed it. And the frequency threshold dropped back down to three days a month. Rome V also added that the pain cannot be continuous, in order to separate IBS from centrally mediated abdominal pain syndrome.^4,5

The symptoms, and the four subtypes

Photo: cottonbro studio / https://www.pexels.com

The core list is familiar: abdominal pain or cramping, usually tied to bowel movements; excess gas and bloating; diarrhea, constipation, or alternating between the two. Cleveland Clinic adds two that people often do not think to mention — mucus in the stool, and the feeling of not having finished.¹

One detail trips up a lot of self-diagnosis: pain or discomfort is required. Bloating on its own is not IBS. Constipation on its own is not IBS. Those are real, common and treatable — they are simply filed under different names.⁴

The subtypes are sorted by what your stools look like on the days they are abnormal, not across all your bowel movements. That is the part most articles get wrong:

• IBS-C — mostly hard or lumpy
• IBS-D — mostly loose or watery
• IBS-M — a genuine mix of both
• IBS-U — unclassified; it does not sit neatly in any of the above

Subtype is worth pinning down, because treatment diverges from that point onward. The American College of Gastroenterology puts it plainly: categorizing patients by an accurate IBS subtype improves therapy.⁹

Why did this happen to me?

Sometimes there is a real answer. Roughly one in ten people develop IBS in the year after a bout of infectious gastroenteritis — food poisoning, a stomach bug, traveler’s diarrhea — and their risk is about four times that of people who did not have one.¹² It runs higher after a parasitic infection: 41.9% in the pooled data, against 13.8% after a bacterial one.¹²

Post-infectious IBS is a recognized entity. If your symptoms started after a memorable week spent near a foreign bathroom, that is very likely what happened, and it is worth telling whoever is treating you.

More often there is no single cause. Genetics, gut sensitivity, previous antibiotic exposure, the state of the gut microbiome, stress and mood all turn up in the research. Anxiety and depression accompany IBS at roughly three times background rates.²⁹ Which way that arrow points is genuinely unsettled, and it is not a claim that IBS is caused by worrying.

Getting diagnosed is faster than it used to be

Photo: Cedric Fauntleroy / https://www.pexels.com

This is where standard advice has moved furthest, and where most articles are still a decade behind.

IBS used to be described as a diagnosis of exclusion: you got scoped, scanned and tested until nothing turned up, and what was left was IBS. The ACG’s 2021 guideline recommends the opposite — "a positive diagnostic strategy as compared to a diagnostic strategy of exclusion," a strong recommendation on high quality evidence.⁹ The British Society of Gastroenterology agrees: clinicians should make a positive diagnosis "based on symptoms, in the absence of alarm symptoms or signs, and abnormalities on simple blood and stool tests."¹⁰

The International Foundation for Gastrointestinal Disorders puts the same thing in plainer words: "A knowledgeable healthcare provider can diagnose IBS by careful review of your symptoms, a physical examination, and selected diagnostic procedures that are often limited to a few basic tests."²

What "a few basic tests" usually means: a blood count and C-reactive protein; a celiac blood test if diarrhea is part of the picture (a strong recommendation); and fecal calprotectin to rule out inflammatory bowel disease.^9,10

What it does not mean: a routine colonoscopy under 45 with no warning signs, routine stool testing for pathogens, or food allergy and sensitivity panels for everybody. ACG recommends against all three.⁹ If someone is selling you a food-sensitivity blood test, that is a business model, not a guideline.

Two things worth ruling out

Celiac disease. Biopsy-proven celiac is meaningfully more common among people with IBS symptoms than among controls, which is why the blood test is a strong recommendation when diarrhea is involved.¹³ It is one blood draw.

Bile acid diarrhea. In 184 patients with diarrhea-predominant IBS or functional diarrhea and no obvious risk factors, 38% turned out to have primary bile acid diarrhea — a distinct condition with its own treatment.¹⁴ It is under-tested. If diarrhea is the whole story for you, it is worth raising by name.

Food: what the evidence actually supports

Photo: Katya Wolf / https://www.pexels.com

Every body and every microbiome is different, and managing IBS looks different from one person to the next. That is not a shrug — it is the reason the most useful first step is also the least glamorous one.

Start with a food and symptom diary

Two weeks, kept honestly: what you ate, when, what happened afterwards, and what else was going on that day. Hunting triggers from memory is unreliable, because the gap between a meal and a reaction can be hours, and because a bad week at work confounds absolutely everything.

A diary also gives whoever you see something concrete to work from, which shortens the whole process considerably.

Fiber: the type matters more than the amount

The old advice — more fiber might help, less fiber might also help — is not advice. The guidelines are far more specific. ACG: "soluble, but not insoluble, fiber be used to treat global IBS symptoms," a strong recommendation on moderate quality evidence.⁹ That makes it one of the strongest dietary recommendations in the entire document.

BSG adds the practical detail: soluble fiber such as ispaghula (psyllium) works, while insoluble fiber like wheat bran "should be avoided as it may exacerbate symptoms." Start low, around 3–4 g a day, and build up gradually so you do not simply trade one kind of bloating for another.¹⁰

Soluble sources worth knowing: oats, psyllium husk, barley, apples, citrus and carrots. Our guide to high-fiber foods has more, though note that legumes are excellent fiber and also high in FODMAPs, which brings us to the next bit.

The low FODMAP diet, done properly

FODMAPs are fermentable short-chain carbohydrates: oligosaccharides, disaccharides (lactose), monosaccharides (fructose) and polyols. They are frequently described as "fermentable fibers," which is wrong — lactose and fructose are sugars. The distinction matters when you are trying to work out what to eat.

ACG recommends "a limited trial of a low FODMAP diet," a conditional recommendation on very low quality evidence.⁹ BSG calls it a second-line dietary therapy and says implementation "should be supervised by a trained dietitian," with FODMAPs "reintroduced according to tolerance."¹⁰ NICE says exclusion-diet advice should only come from a healthcare professional with dietary expertise.¹¹

Three things people routinely get wrong about it. It is not first-line. It is not permanent. And it is not a do-it-yourself project. The restriction phase is short by design; the reintroduction phase is the actual point, because it tells you which FODMAPs are your problem — usually one or two, rarely all of them. Skip that phase and you have talked yourself into a needlessly narrow diet for life.

Our FODMAPs explained article covers which foods sit where.

Coffee, dairy and water

Coffee. NICE suggests capping tea and coffee at three cups a day.¹¹ But the population data do not make coffee a cause of IBS: a meta-analysis of 432,022 people found coffee drinkers had lower odds of having IBS, with a pooled odds ratio of 0.84.¹⁵ Coffee does stimulate the colon in most people, which is why it can feel like a trigger. Treat it as a personal variable to test, not a villain to banish.

Dairy. Worth testing rather than assuming. Lactose is one FODMAP among several, and lactose intolerance is a separate, diagnosable condition that regularly gets folded into an IBS label. ACG advises against blanket food-allergy and sensitivity testing, but reproducible symptoms are worth raising with a clinician.⁹ Our piece on food allergy versus food intolerance untangles the two. Cutting an entire food group indefinitely on a hunch has a real cost.

Water. NICE: "Drink at least 8 cups of fluid per day, especially water or other non-caffeinated drinks, for example herbal teas."¹¹ If diarrhea is a regular feature, you will need more than baseline simply to break even.

Movement, stress and sleep

Photo: Filip Marcus Adam / https://www.pexels.com

Exercise. BSG is unusually direct: "All patients with IBS should be advised to take regular exercise" — a strong recommendation.¹⁰ A 2026 meta-analysis of ten studies and 437 patients found symptom-severity scores improved more with exercise than without, while quality-of-life and anxiety scores did not reach statistical significance, and there is still no agreed exercise prescription for IBS.¹⁶ Cleveland Clinic’s 150 minutes of moderate activity a week — about half an hour, five days — is a sensible target.¹

The mind–gut part. This is where some of the better evidence sits. ACG suggests gut-directed psychotherapies for global IBS symptoms.⁹ BSG rates both IBS-specific cognitive behavioral therapy and gut-directed hypnotherapy as strong recommendations.¹⁰ A 2026 network meta-analysis of 68 randomized trials and 6,694 participants found CBT, dynamic psychotherapy, structured self-management and gut-directed hypnotherapy all outperformed waiting-list control, with the authors flagging possible publication bias and low certainty overall.¹⁷

Gut-directed hypnotherapy earns a specific mention because it sounds like a stage act and is not one. It is a structured clinical protocol, and it carries more guideline support than most things marketed for IBS.

Smoking. Quitting is worth doing, and the honest reason is not IBS. Smoking is associated with reduced diversity in the gut microbiome¹⁹ and it is a well-established risk factor for Crohn’s disease. For IBS specifically, the best-designed study — three population-based cohorts — found a link only among people smoking twenty or more cigarettes a day, and only with the diarrhea subtype.¹⁸

Sleep. Poor sleep and gut symptoms tend to feed each other, and sleep is usually easier to influence than the gut is. We have written about sleep and gut health separately.

What about probiotics?

Here is the full picture, including the parts that are not flattering.

The major bodies disagree with each other, openly and in print:

• AGA (2020) recommends probiotics for IBS "only in the context of a clinical trial," and files the question under knowledge gap.²⁰
• ACG (2021): "We suggest against probiotics for the treatment of global IBS symptoms." Conditional recommendation; very low quality of evidence.⁹
• BSG (2021): probiotics "may be an effective treatment for global symptoms and abdominal pain in IBS, but it is not possible to recommend a specific species or strain." Weak recommendation; very low quality evidence. It is reasonable to try one for up to 12 weeks and stop if nothing changes.¹⁰
• NICE: if you choose to try one, take it for at least four weeks at the manufacturer’s dose while monitoring the effect.¹¹
• World Gastroenterology Organisation (2023): effects are strain-specific and dose-specific, so results with one product do not transfer to another.²¹

The underlying trials explain why the guidelines cannot agree. A 2026 meta-analysis of 40 randomized trials found probiotics improved symptom-severity scores on average but not quality of life — and its trial sequential analysis concluded the evidence "has not reached the required information size," with no signal of benefit, futility or harm.²² An umbrella review of 27 systematic reviews the same year found methodological quality low or critically low across the board, with only 1% of outcomes rated high certainty. Side effects were comparable to placebo.²³

Which leaves an unsatisfying but accurate position: nobody can honestly promise you a probiotic will fix your IBS, and nobody can honestly tell you it cannot help. The practical rule that survives all of it is NICE’s — one product, at its labeled dose, for four weeks, then an actual decision.¹¹

One over-the-counter option does have clearer support. ACG suggests peppermint oil for global IBS symptoms.⁹ BSG concurs and flags the common side effect, which is reflux.¹⁰ It rates better in the guidelines than probiotics do, and that is worth knowing before you spend money.

Living with IBS

Photo: Kindel Media / https://www.pexels.com

The reassuring part is genuinely reassuring. It is worth being precise about which parts.

IBS does not shorten your life. IFFGD states it flatly: "Although IBS does not shorten a person’s life span, it is associated with a large health care and economic burden."² A UK Biobank study of 502,369 people followed for a median of 13.7 years found people with an IBS diagnosis had lower all-cause mortality than those without.²⁴

It does not cause colon cancer. A pooled analysis covering 654,764 people with IBS found colorectal polyps significantly less common than in controls, and colorectal cancer lower but not significantly so.²⁵ Cleveland Clinic says the same: IBS "doesn’t cause tissue damage in your GI tract or increase your risk of more serious conditions, like colon cancer."¹

One caveat we would rather include than leave out. A 2026 UK Biobank cohort of 447,631 people found a higher rate of later inflammatory bowel disease diagnoses among people with IBS (hazard ratio 1.68, and 2.04 for Crohn’s), still elevated beyond ten years.²⁶ Some of that is almost certainly early IBD being labeled IBS first. It is the reason your clinician checks calprotectin — not something to expect.

And "not dangerous" is not the same as "not serious." IBS takes a real bite out of quality of life. It travels with anxiety and depression at around three times background rates.²⁹ And historically, people with IBS have had their gallbladders removed at roughly three times the rate of everyone else, and appendectomies and hysterectomies at about twice.^27,28

An accurate diagnosis is not just a label. It is the thing that stops the search.

Which is the strongest argument going for getting diagnosed properly and early, by someone who recognizes the pattern — rather than arriving at the same place by way of a series of procedures.

A note about Flourish

Flourish is a living liquid probiotic taken daily by adults for general digestive and microbiome support — eleven strains from five families, fermented together as one culture, third-party tested every batch.

It is not a treatment for IBS. On the current evidence, no probiotic is, which is exactly what the guidelines above say. If you have IBS and you want to try a probiotic anyway, the sensible way to do it is NICE’s way: one product, at its labeled dose, for four weeks, and a real decision at the end of it — after a conversation with your provider, particularly if you take prescription medication.

Flourish is a dietary supplement intended to support digestive and microbiome health. It is not a treatment for irritable bowel syndrome or any other condition. Speak to your healthcare provider before starting any supplement, and follow the dosage on the label.

Ready to try a living probiotic?

Eleven living strains. One shared culture. One daily shot.

Shop Flourish Original  ·  What’s inside  ·  Product FAQ

A few questions we hear a lot

Is IBS all in my head?

No. It is a disorder of gut–brain interaction, which means the communication between the two is involved — not that the symptoms are invented. The pain, the urgency and the bloating are all real physical events.³

I was told years ago that I did not quite meet the criteria. Has that changed?

Possibly. Rome V, published in May 2026, reintroduced "discomfort" alongside pain and lowered the frequency threshold from once a week to three days a month.^4,5 People who fell just outside Rome IV may sit inside Rome V. It is a reasonable thing to raise at your next appointment.

Do I need a colonoscopy?

Probably not, if you are under 45 and have no alarm features — ACG recommends against routine colonoscopy in exactly that situation.⁹ If you do have alarm features, or you are due for colorectal cancer screening on age grounds, that is a different conversation and worth having.

Should I go on a low FODMAP diet?

Not as a first move, and not alone. It is a second-line therapy meant to be supervised by a dietitian, run for a limited period, and followed by structured reintroduction.^9,10,11 Soluble fiber has stronger guideline backing and is far easier to try.⁹

Will a probiotic help my IBS?

Honestly, nobody can tell you in advance. ACG suggests against them, AGA calls it a knowledge gap, BSG and NICE say they may help but cannot name a strain, and the trial data have not accumulated far enough to settle it.^{9,10,11,20,22} If you try one, follow NICE’s rule: four weeks at the labeled dose, then decide.

My symptoms started after food poisoning. Is that a thing?

Very much so. Post-infectious IBS follows around one in ten cases of infectious gastroenteritis within a year, at roughly four times the background risk.¹² Mention it — it changes how your clinician thinks about the timeline.

Can IBS turn into something worse?

IBS itself does not shorten life or cause colon cancer.^1,2,24,25 One 2026 cohort did find higher rates of later inflammatory bowel disease diagnoses among people carrying an IBS label, which is part of why the initial workup includes a calprotectin test.²⁶ If your symptoms change character, get seen again rather than assuming it is the same thing.

Important information

This article is for general education and is not a substitute for professional medical advice, diagnosis, or treatment. IBS shares symptoms with several other conditions, some of which need different treatment, so a proper assessment matters. Guideline recommendations are summarized here in brief; the linked documents contain the full wording, the strength of each recommendation and the quality of the underlying evidence. Probiotic effects are specific to the strain, the dose and the population studied, and evidence for one product does not transfer to another. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Sources

1. Cleveland Clinic (last reviewed 16 November 2023). Irritable Bowel Syndrome (IBS). Source
2. International Foundation for Gastrointestinal Disorders (n.d.). Irritable Bowel Syndrome. Source
3. Drossman, D. A., Chang, L., & Tack, J. (2026). Disorders of gut-brain interaction and the Rome V process. Gastroenterology, 170(6), 1083–1098. Source
4. Corsetti, M., Shin, A., Lacy, B. E., Cash, B. D., Simrén, M., Schmulson, M. J., Hou, X., & Lembo, A. (2026). Bowel disorders. Gastroenterology, 170(6), 1261–1282 — the Rome V classification of bowel disorders, including the IBS criteria and subtypes. Source
5. Staller, K., Goodoory, V. C., Khasawneh, M., Black, C. J., & Ford, A. C. (2026). The Rome V criteria for the diagnosis of irritable bowel syndrome in secondary care: a diagnostic accuracy study. The Lancet Gastroenterology & Hepatology, 11(9), 812–820 — 726 patients; sensitivity 66.1%, specificity 80.1%. Source
6. Sperber, A. D., Hreinsson, J. P., Simrén, M., et al. (2026). Rome V global epidemiology and validation survey. Gut, advance online publication, 18 August 2026 — 28,771 adults in 15 countries; IBS 8.5%. Source
7. Palsson, O. S., Whitehead, W., Törnblom, H., Sperber, A. D., & Simrén, M. (2020). Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom. Gastroenterology, 158(5), 1262–1273.e3. Source
8. Oka, P., Parr, H., Barberio, B., Black, C. J., Savarino, E. V., & Ford, A. C. (2020). Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology, 5(10), 908–917. Source
9. Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021). ACG clinical guideline: management of irritable bowel syndrome. The American Journal of Gastroenterology, 116(1), 17–44. Source
10. Vasant, D. H., Paine, P. A., Black, C. J., et al. (2021). British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut, 70(7), 1214–1240. Source
11. National Institute for Health and Care Excellence (2008, updated 2017). Irritable bowel syndrome in adults: diagnosis and management (Clinical guideline CG61). Source
12. Klem, F., Wadhwa, A., Prokop, L. J., et al. (2017). Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology, 152(5), 1042–1054.e1 — 45 studies, 21,421 individuals. Source
13. Irvine, A. J., Chey, W. D., & Ford, A. C. (2017). Screening for celiac disease in irritable bowel syndrome: an updated systematic review and meta-analysis. The American Journal of Gastroenterology, 112(1), 65–76. Source
14. Shiha, M. G., Ashgar, Z., Fraser, E. M., Kurien, M., & Aziz, I. (2020). High prevalence of primary bile acid diarrhoea in patients with functional diarrhoea and irritable bowel syndrome-diarrhoea. EClinicalMedicine, 25, 100465. Source
15. Lee, J. Y., Yau, C. Y., Loh, C. Y. L., et al. (2023). Examining the association between coffee intake and the risk of developing irritable bowel syndrome: a systematic review and meta-analysis. Nutrients, 15(22), 4745 — eight studies, 432,022 patients; pooled OR 0.84. Source
16. Wu, J., Du, S., Sun, Y., Ye, J., & Xu, Y. (2026). Evaluation of the effectiveness of exercise therapy for irritable bowel syndrome: a systematic review and meta-analysis. Frontiers in Medicine, 13, 1771521 — 10 studies, 437 patients. Source
17. Khasawneh, M., Thakur, E. R., Goodoory, V. C., Moayyedi, P., Black, C. J., & Ford, A. C. (2026). Efficacy of gut-brain neuromodulators and brain-gut behaviour therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut, advance online publication — 68 RCTs, 6,694 participants. Source
18. Talley, N. J., Powell, N., Walker, M. M., et al. (2021). Role of smoking in functional dyspepsia and irritable bowel syndrome: three random population-based studies. Alimentary Pharmacology & Therapeutics, 54(1), 32–42. Source
19. Antinozzi, M., Giffi, M., Sini, N., et al. (2022). Cigarette smoking and human gut microbiota in healthy adults: a systematic review. Biomedicines, 10(3), 510. Source
20. Su, G. L., Ko, C. W., Bercik, P., Falck-Ytter, Y., Sultan, S., Weizman, A. V., & Morgan, R. L. (2020). AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. Gastroenterology, 159(2), 697–705. Source
21. World Gastroenterology Organisation (2023). Probiotics and prebiotics: WGO global guideline. Source
22. Tang, A. S. P., Quek, J., Sulaimi, F., et al. (2026). Probiotics for irritable bowel syndrome: an updated systematic review and meta-analysis with trial sequential analysis. Journal of Gastroenterology and Hepatology, 41(4), 1131–1146 — 40 RCTs; GRADE certainty low. Source
23. Ballena-Caicedo, J., Zuzunaga-Montoya, F. E., Acosta-Porzoliz, R., et al. (2026). Probiotics in irritable bowel syndrome: an umbrella review of 27 systematic reviews on methodological quality and certainty of evidence. Journal of Clinical Medicine, 15(5), 1727. Source
24. Staller, K., Olen, O., Sodergren, E., et al. (2024). The time-dependent association between irritable bowel syndrome and all-cause and cause-specific mortality: a prospective cohort study within the UK Biobank. The American Journal of Gastroenterology, 119(7), 1373–1382 — 502,369 participants, median 13.7 years. Source
25. Vichos, T., Rezaie, A., Vichos, P., Cash, B., & Pimentel, M. (2023). Irritable bowel syndrome is not associated with an increased risk of polyps and colorectal cancer: a systematic review and meta-analysis. Digestive Diseases and Sciences, 68(6), 2585–2596. Source
26. Song, H., Zhou, Y., Liu, S., et al. (2026). Long-term risk of inflammatory bowel disease in patients with irritable bowel syndrome. Journal of Gastroenterology, 61(2), 139–149 — UK Biobank, 447,631 participants. Source
27. Longstreth, G. F., & Yao, J. F. (2004). Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology, 126(7), 1665–1673 — 89,008 health examinees. Source
28. Longstreth, G. F. (2007). Avoiding unnecessary surgery in irritable bowel syndrome. Gut, 56(5), 608–610. Source
29. Zamani, M., Alizadeh-Tabari, S., & Zamani, V. (2019). Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, 50(2), 132–143 — 73 studies. Source
30. Sperber, A. D., Bangdiwala, S. I., Drossman, D. A., et al. (2021). Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology, 160(1), 99–114.e3. Source